132 related articles for article (PubMed ID: 23841765)
1. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
Goldberg R; Smith E; Bell S; Thompson A; Desmond PV
Intern Med J; 2013 Jul; 43(7):835-6. PubMed ID: 23841765
[No Abstract] [Full Text] [Related]
2. Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
Beysel S; Yeğın ZA; Yağci M
Turk J Gastroenterol; 2010 Jun; 21(2):197-8. PubMed ID: 20872342
[No Abstract] [Full Text] [Related]
3. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
4. Deafness associated with the use of Bortezomib in multiple myeloma.
Chim CS; Wong LG
Acta Oncol; 2008; 47(2):323-4. PubMed ID: 17851876
[No Abstract] [Full Text] [Related]
5. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Fang B; Song Y; Ma J; Zhao RC
Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
[No Abstract] [Full Text] [Related]
6. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
Duek A; Feldberg E; Haran M; Berrebi A
Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
[No Abstract] [Full Text] [Related]
7. Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib?
Cabanillas M; Peteiro C; Toribio J
Dermatology; 2006; 213(3):246-7. PubMed ID: 17033179
[No Abstract] [Full Text] [Related]
8. Chalazia associated with bortezomib therapy for multiple myeloma.
Grob SR; Jakobiec FA; Rashid A; Yoon MK
Ophthalmology; 2014 Sep; 121(9):1845-7.e3. PubMed ID: 24974380
[No Abstract] [Full Text] [Related]
9. The impact of bortezomib on the risk of thrombosis in multiple myeloma.
Connolly G
Leuk Res; 2011 Feb; 35(2):145-6. PubMed ID: 20952063
[No Abstract] [Full Text] [Related]
10. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.
Tanaka H; Sakuma I; Hashimoto S; Takeda Y; Sakai S; Takagi T; Shimura T; Nakaseko C
J Clin Exp Hematop; 2012; 52(1):67-9. PubMed ID: 22706534
[TBL] [Abstract][Full Text] [Related]
11. Hyperlipidemia in a myeloma patient after bortezomib treatment.
Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
[No Abstract] [Full Text] [Related]
12. Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
Kim JS; Roh HS; Lee JW; Lee MW; Yu HJ
Int J Dermatol; 2012 Dec; 51(12):1491-3. PubMed ID: 22998496
[No Abstract] [Full Text] [Related]
13. Bortezomib-induced cutaneous lupus in a patient with myeloma.
Heelan K; McKenna DB
J Dermatol; 2013 Feb; 40(2):123-4. PubMed ID: 23078265
[No Abstract] [Full Text] [Related]
14. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
Dun X; Yuan Z; Fu W; Zhang C; Hou J
Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
[No Abstract] [Full Text] [Related]
15. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
16. Bortezomib-induced acute pancreatitis.
Elouni B; Ben Salem C; Zamy M; Sakhri J; Bouraoui K; Biour M
JOP; 2010 May; 11(3):275-6. PubMed ID: 20442528
[No Abstract] [Full Text] [Related]
17. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
[No Abstract] [Full Text] [Related]
18. Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.
Cornelis T; Beckers EA; Driessen AL; van der Sande FM; Koek GH
Clin Toxicol (Phila); 2012 Jun; 50(5):444-5. PubMed ID: 22462599
[TBL] [Abstract][Full Text] [Related]
19. Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma?
Dasanu CA; Alexandrescu DT
J Clin Oncol; 2009 May; 27(13):2293-4; author reply 2294-6. PubMed ID: 19307496
[No Abstract] [Full Text] [Related]
20. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
[No Abstract] [Full Text] [Related]
[Next] [New Search]